Zepbound: FDA approves new version of Eli Lilly’s Mounjaro diabetes drug to assist with weight loss
A new version of the popular diabetes treatment Mounjaro can be sold as a weight-loss drug, U.S. regulators announced in early November. The U.S. Food and Drug Administration approved Eli Lilly’s drug, named Zepbound. The drug, also known as tirzepatide, helped dieters lose as much as 40 to 60 pounds in testing. Zepbound is the latest diabetes drug approved for chronic weight management, joining Novo Nordisk’s Wegovy, a high-dose version of its diabetes treatment Ozempic. Both are weekly injections. The FDA approved Lilly’s drug for people who are considered obese, with a body mass index of 30 or higher,...
Read More